DAFTAR PUSTAKA
1. Jemal A, Siegel R, Xu J ,Ward E. Cancer Statistics, 2010. CA Cancer J Clin
2010;60;277-300
2. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. JClin Oncol
2007;25:2873-83.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et
al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in
patients with stage III and stage IV ovarian cancer. N Engl J Med
1996;334:1-6.
4. Raungkaewmanee S. Platelet to lymphocyte ratio as a prognostic factor for
epithelial ovarian cancer.J Gynecol Oncol Vol. 23,2012 No. 4:265-273
5. Asher V,et al. Preoperative platelet lymphocyte ratio as an independent
prognostic marker in ovarian cancer. Clin Transl Oncol (2011) 13:499-503
6. Oh J,et al. Preoperative Thrombocytosis Is an Independent Poor Prognostic
Factor in Patients with Epithelial Ovarian Cancer. Clin Exp Thromb Hemost
2014;1(1):17-21
7. Zhou X.Prognostic Value of PLR in Various Cancers: A Meta-Analysis. PLOS
One. 9(6).2014: 1-8
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA
Cancer J Clin. 2005;55(2):74108.
9. American Cancer Society ovarian cancer statistics
http://our.cancer.org/docroot/CRI/content/CRI_2_2_3X_Survival_rates_for_ov arian_cancer_33.asp?sitearea
10. SEER Stat Fact Sheets: Ovary Cancer.National Cancer Institute. 2014
11. Berek JS. Natarajan Sathima. Ovarian and Fallopian Tube Cancer. Berek &
Novak’s Gynecology. Lippincott William and Wilkins. 14th edition.2007; 1457
– 1503
12. Hacker FN. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. Berek
and Hacker's Gynecologic Oncology, Lippincott Williams & Wilkins. 5th
Edition. Chapter 14.2010: 576-83
13. Danukusumo D. Akurasi pembedahan kanker ovarium, Tinjauan retrospektif
di RS Cipto Mangunkusumo 1991. Simposium KeganasanOvarium, PTP
POGI IX, 1991, Bandung.
14. Fadlan. Tinjauan Kasus Neoplasma Ovarium Ganas di Rumah Sakit
Dr.Pirngadi Medan (1981–1990). Tesis pada Bagian Obstetri dan Ginekologi
Fakultas Kedokteran USU, Medan, 1993
15. Hardiman A, Noviani R, dkk. Kebijakan dan Pokok – pokok Kegiatan
Pengendalian Penyakit Kanker di Indonesia. Rumah Sakit Kanker Darmais.
Indonesia Journal of Cancer. Volume 1, No 2.Jakarta. April – Juni 2007
16. Aziz MF, Andrijono, Saifuddinn AB. Buku acuan Nasional Onkologi
Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo. Departemen
Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama.
2006; 469 – 527
17. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface
epithelium:Biology, endocrinology, and pathology. Endocr Rev
2001;22(2):25588.
18. Okamura H, Katabuchi H, Nitta M, Ohtake H. Structural changes and cell
properties of human ovarian surface epithelium in ovarian pathophysiology.
19. Partheen K. New prognostic marker In Stage III Serous Ovarian
Adenocarcinomas. Department of Oncology Institute of Clinical Sciences The
Sahlgrenska Academy at University of Gothenburg.2008
20. Mandij A. Ovarian cancer stage III/IV: poor prognostic factors. Archive of
Oncology 2001;9(1):13-6.
21. Tognon G, et al. Prognostic factor in early stage ovarian cancer. ecancer
2013, 7:325
22. Tang Li,et al. Clinical characteristics and prognosis of epithelial ovarian
cancer in young women.Chinese Journal of Cancer 2008:27:9, 238-241
23. Ries LAG, et al SEER Cancer Statistics Review, 19752003,National Cancer
Institute. Bethesda, MD,<http://seer.cancer.gov/csr/1975_2003/>, based on
November 2005 SEER data submission,posted to the SEER web site, 2006.
24. Maas HA, et al. The influence of age and comorbidity on treatment and
prognosis of ovarian cancer: A population based study. Gynecol Oncol
2005;97(1):1049
25. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease
stage at diagnosis, and mortality. Cancer 1993;71(2 Suppl):51723.
26. Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer
1993;71(2Suppl):5249..
27. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model
for ovarian cancer. Br J Cancer 2001;85(7):94452.
28. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman
WT, et al. Carcinoma of the ovary. In: Pecorelli S, ed. Twenty-Sixth Annual
Report on the Results of Treatment in Gynaecological Cancer. Int J Gynecol
29. WHO. Pathology and genetics. Tumours of the breast and female genital
organs.Tavassoli AF, Devilee P, editors. Lyon: IARCPress, 2003. pp. 114145.
30. Suhonen K. Prognostic Role of Cell Adhesion Factors and Angiogenesis in
Epithelial Ovarian Cancer. Institute of Clinical Medicine University of Kuopio.
Kuopio. 2007
31. Kobel M, et al. Differences in tumor type in low-stage versus high-stage
ovarian carcinomas. Int J Gynecol Pathol 2010, 29(3):203-211.
32. Kobel M, et al. Tumor type and substage predict survival in stage I and II
ovarian carcinoma: insights and implications. Gynecol Oncol 2010,
116(1):50-56
33. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of
cytoreductive surgery on recurrence free interval and survival in smallvolume
stage III epithelial ovarian cancer: A Gynecologic Oncology Group study.
Gynecol Oncol 1992;47(2):15966.
34. Grivvenikov S I,et al.Immunity, Inflammation and Cancer. Cell 140, 883–899,
March 19, 2010
35. Hanahan D, Weinberg W A. Hallmark of Cancer: The Next Generation. Cell
144, March 4, 2011
36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. The
Lancet.Vol 357. 2001
37. MacDonald N. Chronic inflammatory states: their relationship to cancer
prognosis and symptoms.J R Coll Physicians Edinb 2011; 41:246–53
38. Milne K,et al.Absolute lymphocyte count is associated with survival in ovarian
cancer independent of tumor infiltrating lymphocytes.Journal of Translational
39. Stone R L. The role of platelet in ovarian carcinoma. UT GSBS Dissertations
and Theses (Open Access). Paper 46.2010
40. Noe B, Goerge T, Wagner DD. Platelets: Guardians of Tumor Vasculature.
American Association for Cancer Research.2009; 69: (14).
41. Ma X,et al. Prognostic significance of thrombocytosis, platelet parameters and
aggregation rates in epithelia ovarian cancer.J. Obstet. Gynaecol. 2014.Res.
Vol. 40, No. 1: 178–183,
42. Bambace NM, Holmes E. The platelet contribution to cancer progression.
Journal of Thrombosis and Haemostasis 9; 237-249.
43. Carr B I. Platelets and Cancer. Seminars in oncology.2014
44. Rochet N, et al. The role of complete blood count in prognosis. Oncology &
Hematology Review, 2012;8(1):76–82
45. Choi N, et al. Intracellular localization and release of platelet vascular
endothelial growth factor. Journal of Undergraduate Life Sciences.2009
46. Maloney JP, et al. In vitro release of vascular endothelial growth factor during
platelet aggregation. American Physiological Society.1998.
47. Egan K, et al. Platelet Adhesion and Degranulation Induce Pro-Survival and
Pro-Angiogenic Signalling in Ovarian Cancer Cells. Plos One Vol.6.2011,p;1
48. Burger RA: Overview of anti-angiogenic agents in development for ovarian
cancer. Gynecol Oncol 2011, 121(1):230-238.
49. Pilko SK,et al.The elevated preoperative platelet-tolymphocyte ratio predicts
poor prognosis in breast cancer patients. British Journal of Cancer (2014)
50. Seretis C,et al. Enhancing the Accuracy of Platelet to Lymphocyte Ratio after
Adjustment for Large Platelet Count:A Pilot Study in Breast Cancer Patients.
